Corporate Banner
Satellite Banner
Technology Networks Header
Monday, December 22, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
QIAGEN Expands Product Portfolio for NGS and Cancer Research
Saturday, April 05, 2014
New innovative product launches at AACR Annual Meeting add to broad portfolio of NGS solutions.

New Application of TAP’s Automated Cell Culture System at AACR
Saturday, April 05, 2014
Offers rapid production and consistent quality of NCI 60 cancer cell line panel.

Illumina Expands Product Portfolio
Thursday, April 03, 2014
End-to-end genomics solutions will transform the future of oncology.

PGDx Raises $2.8 Million and Launches its METDetect™ Assay
Thursday, April 03, 2014
First-in-class CLIA assay for detection of tumor-specific gene amplifications using circulating cell-free DNA.

Cancer Genetics Expands BioDiscovery's Nexus Copy Number Platform
Thursday, April 03, 2014
Expansion to identify novel biomarkers predictive of cancer outcomes.

Physiologically Relevant Cell Culture Handbook
Tuesday, April 01, 2014
48-page handbook is also a resource for neuroscience, drug discovery and regenerative medicine applications.

Promega Introduces Maxwell 16 LEV RNA FFPE Kit
Tuesday, April 01, 2014
New kit provides high yield, pure and amplifiable RNA from FFPE mammalian tissue samples.

Identifying Epigenetic Biomarkers for Prostate Cancer
Tuesday, April 01, 2014
IDT qPCR assays and probes facilitate the development of predictive epigenetic biomarkers.

GenTegra LLC Launches New RNA Ambient Stabilization Product
Friday, March 28, 2014
Protect RNA samples immediately, and for all its tomorrows.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 667
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn